Stratifying Risk and Targeting Immunosuppressive Strategies

Transplantation Proceedings

Volumn 40, Issue 10 SUPPL., 2008, Pages

  Russ, G ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACNE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FOLLICULITIS; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; STOMATITIS;

CALCINEURIN; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 57649091648     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.002     Document Type: Article

References (10)

1. Mathew T.H., McDonald S.P., and Russ G.R. Donor and recipient risk factors and choice of immunosuppression determine long-term outcome in renal transplantation. Transplant Proc 33 (2001) 3400
2. Nankivell B., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
3. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18 (2005) 22
4. Mota A., Arias M., Taskinen E., et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4 (2004) 953
5. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
6. Schena F.P., Vitko S., Wali R., et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18-month results from a randomized, open-label comparative trial. Transplantation 82 Suppl 3 (2006) 412
7. Flechner S., Glyda M., Steinberg S., et al. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study. Transpl Int 20 Suppl 2 (2007) 209
8. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007) 2562
9. Weir M., Wali R., Pearson T.C., et al. Spare-the-Nephron (STN) Trial: updated 1-year efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients. Am J Transplant 7 Suppl 2 (2007) 159
10. Lebranchu Y., Etienne I., Touchard G., et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF). Am J Transplant 7 Suppl 2 (2007) 160